Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Kendra KL, et al. Among authors: carson we 3rd. Nat Med. 2025 Aug 26. doi: 10.1038/s41591-025-03975-2. Online ahead of print. Nat Med. 2025. PMID: 40858972 No abstract available.
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Kendra KL, et al. Among authors: carson we 3rd. Nat Med. 2025 Aug 14:10.1038/s41591-025-03875-5. doi: 10.1038/s41591-025-03875-5. Online ahead of print. Nat Med. 2025. PMID: 40813711 Free PMC article.
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy.
Savardekar H, Stiff A, Liu A, Wesolowski R, Schwarz E, Garbarine IC, Duggan MC, Zelinskas S, Li J, Lapurga G, Abreo A, Savardekar L, Parker R, Sabella J, DiVincenzo MJ, Benner B, Sun SH, Quiroga D, Scarberry L, Xin G, Dey A, Ozato K, Yu L, Hasanov M, Sundi D, Wu RC, Kendra KL, Carson WE 3rd. Savardekar H, et al. Among authors: carson we 3rd. J Clin Invest. 2025 Aug 5;135(19):e181975. doi: 10.1172/JCI181975. eCollection 2025 Oct 1. J Clin Invest. 2025. PMID: 40762981 Free PMC article.
Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers.
Song NJ, Xie J, Jung KJ, Wang Y, Pozniak J, Roda N, Marine JC, Riesenberg BP, Jeon H, Ma A, Cox N, Wethington D, Reynolds K, Xiao T, Li A, Kronen P, Denko N, Carbone DP, Ma Q, Carson WE 3rd, Mundy-Bosse BL, Burd CE, Das J, Chung D, Li Z. Song NJ, et al. Among authors: carson we 3rd. Cancer Discov. 2025 Sep 4;15(9):1835-1857. doi: 10.1158/2159-8290.CD-24-1232. Cancer Discov. 2025. PMID: 40530506
A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade.
Angell CD, Sun SH, Lapurga G, Benner B, Quiroga D, Savardekar H, DiVincenzo MJ, Abood D, Stiff A, Duggan M, Handley D, Nagle E, Howard JH, Shah H, Kendra KL, Carson WE 3rd. Angell CD, et al. Among authors: carson we 3rd. Melanoma Res. 2025 Apr 1;35(2):102-108. doi: 10.1097/CMR.0000000000001023. Epub 2025 Jan 29. Melanoma Res. 2025. PMID: 39883562
Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer.
Schwarz E, Savardekar H, Zelinskas S, Mouse A, Lapurga G, Lyberger J, Rivaldi A, Ringwalt EM, Miller KE, Yu L, Behbehani GK, Cripe TP, Carson WE 3rd. Schwarz E, et al. Among authors: carson we 3rd. Cancer Immunol Res. 2025 Apr 2;13(4):560-576. doi: 10.1158/2326-6066.CIR-24-0775. Cancer Immunol Res. 2025. PMID: 39777457 Free PMC article.
Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.
Schwarz E, Benner B, Wesolowski R, Quiroga D, Good L, Sun SH, Savardekar H, Li J, Jung KJ, Duggan MC, Lapurga G, Shaffer J, Scarberry L, Konda B, Verschraegen C, Kendra K, Shah M, Rupert R, Monk P, Shah HA, Noonan AM, Bixel K, Hays J, Wei L, Pan X, Behbehani G, Hu Y, Elemento O, Chung D, Xin G, Blaser BW, Carson WE 3rd. Schwarz E, et al. Among authors: carson we 3rd. JCI Insight. 2024 Nov 8;9(21):e169927. doi: 10.1172/jci.insight.169927. JCI Insight. 2024. PMID: 39513363 Free PMC article. Clinical Trial.
NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy.
Merchand-Reyes G, Bull MF, Santhanam R, Valencia-Pena ML, Murugesan RA, Chordia A, Mo XM, Robledo-Avila FH, Ruiz-Rosado JD, Carson WE 3rd, Byrd JC, Woyach JA, Tridandapani S, Butchar JP. Merchand-Reyes G, et al. Among authors: carson we 3rd. Front Immunol. 2024 Jun 11;15:1409333. doi: 10.3389/fimmu.2024.1409333. eCollection 2024. Front Immunol. 2024. PMID: 38919608 Free PMC article.
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson WE 3rd. Quiroga D, et al. Among authors: carson we 3rd. Cancer Control. 2024 Jan-Dec;31:10732748241250189. doi: 10.1177/10732748241250189. Cancer Control. 2024. PMID: 38797949 Free PMC article. Clinical Trial.
186 results